WHO seeks clarification from India if cough syrup has been exported to other countries, Pg12

Key Highlights:

• The WHO has requested clarification from India regarding the potential export of a cough syrup linked to over 15 child deaths.
• The cough syrup, Coldrif, is suspected of causing deaths in Madhya Pradesh and Rajasthan.
• Coldrif was manufactured by Sresan Pharmaceuticals, which is currently under investigation.
• The Central government had previously advised against using the fixed-dose combination in children below four years old in December 2023.

Detailed Insights:

• The WHO is awaiting a response from Indian health authorities before deciding whether to issue a Global Medical Products Alert for Coldrif.
• At least 17 children under the age of five have allegedly died in India after consuming cough syrup containing diethylene glycol (DEG).
• Coldrif is prescribed for treating cold and cough symptoms and contains chlorpheniramine maleate, paracetamol, and phenylephrine.
• The Central Drugs Standard Control Organisation has directed state drug controllers to enforce strict testing of raw materials and finished products.

Key Concepts Involved:

• Diethylene Glycol (DEG): A toxic compound that, when ingested, can cause kidney failure and death.
• Fixed-Dose Combination (FDC): A drug product containing two or more active pharmaceutical ingredients in a single dosage form.
• Global Medical Products Alert: An alert issued by the WHO to inform member states and the public about potentially dangerous medical products.